01

Risankizumab Hits PASI 100 in 41% of Adolescents in OptIMMize-1

Phase 3 OptIMMize-1: risankizumab achieved PASI 100 in 41% of adolescents vs 18% on ustekinumab, with responses sustained through 52 weeks in 137 pediatric patients.